Stockscreener 앱 받기
5.58
18.54%
-1.27
시간 외 거래:
5.59
0.010
+0.18%
전일 마감가:
$6.85
열려 있는:
$5.35
하루 거래량:
6.46M
Relative Volume:
9.38
시가총액:
$215.32M
수익:
-
순이익/손실:
$-42.05M
주가수익비율:
-1.9787
EPS:
-2.82
순현금흐름:
$-35.26M
1주 성능:
-24.39%
1개월 성능:
+25.68%
6개월 성능:
+78.85%
1년 성능:
-7.31%
1일 변동 폭
$5.07
$5.705
1주일 범위
$5.07
$7.27
52주 변동 폭
$2.77
$7.82
Protara Therapeutics Inc Stock (TARA) Company Profile
명칭
Protara Therapeutics Inc
전화
646-844-0337
주소
345 PARK AVENUE SOUTH, NEW YORK, NY
TARA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
5.58 | 265.09M | 0 | -42.05M | -35.26M | -2.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-16 | 개시 | Scotiabank | Sector Outperform |
| 2025-03-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-07-10 | 재개 | Guggenheim | Buy |
| 2021-06-04 | 개시 | H.C. Wainwright | Buy |
| 2021-02-17 | 개시 | Oppenheimer | Outperform |
| 2020-10-19 | 개시 | Cowen | Outperform |
| 2020-07-29 | 개시 | Guggenheim | Buy |
모두보기
Protara Therapeutics Inc 주식(TARA)의 최신 뉴스
Protara Therapeutics: Stock Offer Takes the Spotlight - StocksToTrade
Protara Prices $75 Mln Offering To Advance TARA-002 And Broader Pipeline - Nasdaq
Biotech co Protara slides on $75 mln share sale - TradingView
Protara Therapeutics slumps 12%, raises $75M equity at $5.75 per share - MSN
Protara Therapeutics Shares Sink 16% After $75 Mln Public Offering - Nasdaq
Protara Therapeutics (Nasdaq: TARA) prices 13,043,479-share, $75M public deal - Stock Titan
Protara Therapeutics (TARA) Launches $75M Public Offering - GuruFocus
Protara Therapeutics Prices $75 Million Share Offering - marketscreener.com
Will Protara Therapeutics Inc. (1KPA) stock benefit from sector leadershipJuly 2025 Price Swings & Accurate Trade Setup Notifications - Newser
TARA Stock Offering Priced at Lower End of Target Range - GuruFocus
Protara Therapeutics prices $75 million public offering - Investing.com
Protara Announces Pricing of $75 Million Public Offering - The Manila Times
Protara Therapeutics prices $75 million public offering By Investing.com - Investing.com UK
Protara prices public offering of 13.04 million shares at $5.75 each - marketscreener.com
Key Managers Announced for TARA Offering - GuruFocus
Protara Therapeutics Launches Offering of Securities - marketscreener.com
Protara announces proposed public offering - MSN
Protara Therapeutics stock tumbles after $75M public offering By Investing.com - Investing.com UK
Protara Therapeutics stock tumbles after $75M public offering - Investing.com
Protara Therapeutics announces $75 million public offering By Investing.com - Investing.com South Africa
Protara Announces Proposed Public Offering - The Manila Times
Protara Therapeutics Announces $75 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Protara Therapeutics (Nasdaq: TARA) starts $75M stock and pre-funded warrant sale - Stock Titan
Protara Therapeutics (NASDAQ:TARA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naive NMIBC Patients - MarketScreener
Protara Therapeutics: End Of 2025 Proving Eventful Indeed (NASDAQ:TARA) - Seeking Alpha
Why Protara Therapeutics Inc. (1KPA) stock is listed among top recommendationsEarnings Overview Report & Daily Stock Trend Reports - Newser
Protara Therapeutics (NASDAQ:TARA) Receives Buy Rating from HC Wainwright - Defense World
HC Wainwright & Co. Reiterates Protara Therapeutics (TARA) Buy Recommendation - Nasdaq
TARA: HC Wainwright & Co. Reiterates 'Buy' Rating with $23 Targe - GuruFocus
TARA: TARA-002 shows 69% six-month CR and strong safety in BCG naive NMIBC, advancing to registrational trial - TradingView
Protara Reports Updated Interim Phase 2 Data Of TARA-002 In Non-muscle Invasive Bladder Cancer - RTTNews
Protara Therapeutics reports positive results from bladder cancer study - Seeking Alpha
Protara Therapeutics, Inc. (TARA) Jumps 14.6% in Pre-market Trading: After Positive Data Release - Stocks Telegraph
Protara Therapeutics (TARA) Reveals Promising Data from Phase 2 Bladder Cancer Trial - GuruFocus
Protara Therapeutics, Inc. Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial - TradingView
Protara Therapeutics, Inc. Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients - marketscreener.com
Is Protara Therapeutics Inc. (1KPA) stock attractive for dividend growthTrade Entry Summary & Safe Capital Allocation Plans - Newser
Adversity is less terrifying than hope: Protara Therapeutics Inc (TARA) - Setenews
Will Protara Therapeutics Inc. (1KPA) stock sustain uptrend momentum2025 EndofYear Setup & Risk Adjusted Swing Trade Ideas - Newser
After-Hours Spotlight: Jasper, NRx, Unicycive, Spruce, Evaxion, Solana, Protara Gain Post-Close - Nasdaq
Protara to host conference call on TARA-002 bladder cancer trial data - Investing.com Nigeria
Protara Therapeutics to Host Conference Call on December 3 to Discuss Interim Phase 2 Data for TARA-002 in Bladder Cancer - Quiver Quantitative
Protara Therapeutics to Host Conference Call and Webcast to - GlobeNewswire
Is Protara Therapeutics Inc. stock trading near support levelsJuly 2025 Sentiment & Stock Portfolio Risk Control - BỘ NỘI VỤ
Why Protara Therapeutics Inc. stock could outperform in 2025Earnings Miss & Short-Term Swing Trade Alerts - BỘ NỘI VỤ
This Insider Bought 20000.0 Shares In Protara Therapeutics Inc (TARA) - fostersleader.com
HC Wainwright Has Positive Outlook for TARA Q4 Earnings - MarketBeat
Protara Therapeutics, Inc. (NASDAQ:TARA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
HC Wainwright Has Positive Forecast for TARA Q4 Earnings - Defense World
Protara Therapeutics, Inc. (NASDAQ:TARA) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Protara Therapeutics Inc (TARA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.44%
0.91%
자본화:
|
볼륨(24시간):